← Back to Search

Unknown

Part 1: Period 1 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by AbbVie

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 40 days

Awards & highlights

Study Summary

This trial studies how safe and effective a drug combo is in healthy adults.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 40 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 40 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 40 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of 1-OH-Midazolam

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-903

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Midazolam

+13 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: Part 2: Period 2Experimental Treatment2 Interventions

In Period 2 on Day 1, participants will receive ABBV-903 oral tablets. In Period 2 on Day 5, participants will receive liquid midazolam and ABBV-903 oral tablets. Participants will be followed-up for approximately 30 days.

Group II: Part 2: Period 1Experimental Treatment1 Intervention

In Period 1 on Day 1, participants will receive liquid midazolam.

Group III: Part 1: Period 2Experimental Treatment2 Interventions

In Period 2 on Day 1, participants will receive ABBV-903 oral tablets. In Period 2 on Day 10, participants will receive liquid midazolam and ABBV-903 oral tablets. Participants will be followed-up for approximately 30 days.

Group IV: Part 1: Period 1Experimental Treatment1 Intervention

In Period 1 on Day 1, participants will receive liquid midazolam.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ABBV-903

2023

Completed Phase 1

~140

Midazolam

2018

Completed Phase 4

~1910

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor

958 Previous Clinical Trials

502,360 Total Patients Enrolled

ABBVIE INC.Study DirectorAbbVie

397 Previous Clinical Trials

147,074 Total Patients Enrolled

Media Library

ABBV-903 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05895266 — Phase 1

Healthy Subjects Research Study Groups: Part 1: Period 1, Part 1: Period 2, Part 2: Period 1, Part 2: Period 2

Healthy Subjects Clinical Trial 2023: ABBV-903 Highlights & Side Effects. Trial Name: NCT05895266 — Phase 1

ABBV-903 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05895266 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to participate in this clinical investigation?

"Eligibility for this research project necessitates being within 18-65 years old and having a healthy physical condition. Currently, 24 individuals are taking part in the trial."

Answered by AI

Are there any opportunities to partake in this trial currently?

"This particular study is not currently recruiting, as per the information on clinicaltrials.gov; it was first posted and last updated on May 31st 2023. Although this one trial isn't looking for participants, fortunately there are 800 other trials actively enrolling at present."

Answered by AI

Are geriatric patients eligible to participate in this investigation?

"In order to be considered for this trial, patients must possess a minimum age of 18 years and have not yet reached 65."

Answered by AI

Is Part 1: Period 1 of this experiment safe for the participants involved?

"Safety of Part 1: Period 1 was graded as a one, since this is only the first phase of trials and there is limited information regarding its efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers

2023. "A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05895266.